Evan Mayo-Wilson
Biographic Data
| ID | 1942210 |
|---|---|
| NAME | Evan Mayo-Wilson |
| GIVEN NAMES | Evan |
| FAMILY NAME | Mayo-Wilson |
| SIGNATURE | MAYO-WILSON E |
| AFFILIATIONS | E. Mayo-Wilsonis associate professor, Department of Epidemiology and Biostatistics, Indiana University School of Public Health–Bloomington, Bloomington, Indiana |
| VERIFIED | No |
| TOTAL WORKS | 12 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 12 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2007 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
A declaração PRISMA 2020
A declaração dos Principais Itens para Relatar Revisões Sistemáticas e Meta-análises (PRISMA), publicada em 2009, foi desenvolvida para ajudar revisores sistemáticos a relatar de forma transparente por que a revisão foi feita, os métodos empregados e o que os autores encontraram. Na última década, os avanços na metodologia e terminologia de revisões sistemáticas exigiram a atualização da diretriz. A declaração PRISMA 2020 substitui a declaração d…
The PRISMA 2020 statement
Declaración PRISMA 2020
La declaración PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses), publicada en 2009, se diseñó para ayudar a los autores de revisiones sistemáticas a documentar de manera transparente el porqué de la revisión, qué hicieron los autores y qué encontraron. Durante la última década, ha habido muchos avances en la metodología y terminología de las revisiones sistemáticas, lo que ha requerido una actualización de esta guía. La…
The PRISMA 2020 statement
PRISMA 2020 explanation and elaboration
The PRISMA 2020 statement
The PRISMA 2020 statement
Creating a Program to Support Registering and Reporting Clinical Trials at Johns Hopkins University
PROBLEM: The Food and Drug Administration Amendments Act of 2007 (FDAAA) and the National Institutes of Health (NIH) require that many clinical trials register and report results on ClinicalTrials.gov. Noncompliance with these policies denies research participants and scientists access to potentially relevant findings and could lead to monetary penalties or loss of funding. After discovering hundreds of potentially noncompliant trials affiliated …
Should E-Cigarette Regulation Be Based on Randomized Trials or Observational Studies
Challenges stemming from NIH's extended registration and reporting requirements
Developing a Reporting Guideline for Social and Psychological Intervention Trials
Understanding randomized controlled trials of complex social and psychological interventions requires a detailed description of the interventions tested and the methods used to evaluate them. However, randomized controlled trial reports often omit, or inadequately report, this information. Incomplete and inaccurate reporting hinders the optimal use of research, wastes resources, and fails to meet ethical obligations to research participants and c…
Reporting Implementation in Randomized Trials
Randomized controlled trials of public health interventions are often complex: practitioners may not deliver interventions as researchers intended, participants may not initiate interventions and may not behave as expected, and interventions and their effects may vary with environmental and social context. Reports of randomized controlled trials can be misleading when they omit information about the implementation of interventions, yet such data …
No prominent works on this page.
Reporting Implementation in Randomized Trials
Randomized controlled trials of public health interventions are often complex: practitioners may not deliver interventions as researchers intended, participants may not initiate interventions and may not behave as expected, and interventions and their effects may vary with environmental and social context. Reports of randomized controlled trials can be misleading when they omit information about the implementation of interventions, yet such data …
Developing a Reporting Guideline for Social and Psychological Intervention Trials
Understanding randomized controlled trials of complex social and psychological interventions requires a detailed description of the interventions tested and the methods used to evaluate them. However, randomized controlled trial reports often omit, or inadequately report, this information. Incomplete and inaccurate reporting hinders the optimal use of research, wastes resources, and fails to meet ethical obligations to research participants and c…
Challenges stemming from NIH's extended registration and reporting requirements
The PRISMA 2020 statement
Declaración PRISMA 2020
La declaración PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses), publicada en 2009, se diseñó para ayudar a los autores de revisiones sistemáticas a documentar de manera transparente el porqué de la revisión, qué hicieron los autores y qué encontraron. Durante la última década, ha habido muchos avances en la metodología y terminología de las revisiones sistemáticas, lo que ha requerido una actualización de esta guía. La…
The PRISMA 2020 statement
PRISMA 2020 explanation and elaboration
The PRISMA 2020 statement
The PRISMA 2020 statement
Creating a Program to Support Registering and Reporting Clinical Trials at Johns Hopkins University
PROBLEM: The Food and Drug Administration Amendments Act of 2007 (FDAAA) and the National Institutes of Health (NIH) require that many clinical trials register and report results on ClinicalTrials.gov. Noncompliance with these policies denies research participants and scientists access to potentially relevant findings and could lead to monetary penalties or loss of funding. After discovering hundreds of potentially noncompliant trials affiliated …
Should E-Cigarette Regulation Be Based on Randomized Trials or Observational Studies
A declaração PRISMA 2020
A declaração dos Principais Itens para Relatar Revisões Sistemáticas e Meta-análises (PRISMA), publicada em 2009, foi desenvolvida para ajudar revisores sistemáticos a relatar de forma transparente por que a revisão foi feita, os métodos empregados e o que os autores encontraram. Na última década, os avanços na metodologia e terminologia de revisões sistemáticas exigiram a atualização da diretriz. A declaração PRISMA 2020 substitui a declaração d…
Medicine (7 works) · MEDLINE (5 works) · Political science (5 works) · Psychology (5 works) · Meta-analysis and systematic reviews (4 works) · Computer Science (3 works) · Family medicine (3 works) · Guideline (3 works) · Medical education (3 works) · Randomized controlled trial (3 works)